, perhaps increased FGF23 levels would actually be therapeutic. Another attractive but yet unproven view is the "off-target effect" theory. If deficiency of the coreceptor protein Klotho in CKD (19) is impairing the ability of FGF23 to exert its legitimate actions, the remarkably high FGF23 levels could activate off-target effects and stir up multiple rogue pathways. Indeed, this was proposed by Faul and coworkers in describing how the activation of FGF receptor-2 may contribute to cardiocomes (reviewed in ref. 11). Notwithstanding the fact that negative studies are less likely to be published, we are still left with an unprecedented and overwhelming collection of clinical literature linking high FGF23 levels to adverse outcomes, leaving most practitioners to conclude that FGF23 must contribute negatively to the uremic state. The power of epidemiology is of course the sample size, with data secured "in the field," but it suffers from the perpetual limitation of mere association without the power to conclude on causality. When confronted with this body of data, one ponders whether high FGF23 is a mere marker for some underlying sinister menace or a bona fide uremic toxin yet to be caught with the smoking gun. A third paradigm -perhaps considered by some as borderline preposterous -is that the sickest CKD patients may require the highest FGF23 levels, suggesting that FGF23 could be a defensive hormone. Could FGF23 be a "good guy"? Clearly, the current body of evidence cannot proffer definitive proof, but is sufficient to spawn efforts to devise an approach to neutralize the colossally high FGF23 levels in CKD and simply see what happens.
Neutralizing FGF23
While receptor and receptor signaling antagonists are logical candidates for this approach (12) (13) (14) , two groups proceeded to attempt FGF23 neutralization with therapeutic antibodies (15) (16) (17) . Both groups reported that, acutely, anti-FGF23 monoclonal antibodies suppress PTH and raise vitamin D levels, likely via indirect and direct effects, respectively. These effects are nice confirmations of what we know about FGF23 biology and indeed are favorable from the viewpoint of potential therapeutics in CKD. In this issue of the JCI, one of those groups describes the chronic effects of the therapeutic antibody on the pathology in CKD in animal models (17) . In this article, Shalhoub and coworkers showed several salient features of the administration of an anti-FGF23 monoclonal antibody of nanomolar affinity in rodents with an ablation model of CKD. The monoclonal antibody did not change the course of progression of CKD nor did it affect various left ventricular cardiac parameters. These findings are at odds with the proposed models of phosphotoxicity contributing to CKD progression (18) or direct "FGF23 cardiomyopathy" (12) , which further illustrates the complexity of these paradigms. The improvement in static and dynamic bone histomorphometric data The readouts of renal dysfunction Uremia is a highly complex metabolic state. Since the kidney is the principal organ that preserves the constancy of the milieu intérieur, eloquently articulated by Claude Bernard (2), the impact of its dysfunction is widespread and immense. When renal function is compromised, exogenous uremic toxins accumulate and endogenous substances slip to levels incompatible with health. Secondary derangements further compound the state of affairs, cumulating in a downward unrelenting spiral to ultimate metabolic cataclysm. To realistically treat the uremic state, one must devise therapeutic interventions specifically targeted to prevent, arrest, and reverse each of the individual abnormalities of pathogenic significance.
While apparently straightforward in principle, this task is in fact extremely difficult. The derangement of a measurable parameter could merely be a biomarker (e.g., hypercreatinemia), could reflect a pathogenic factor (e.g., hyperphosphatemia, or both, and it is not always easy to distinguish between the two. A mild elevation of urea may be no more than a marker but higher elevations may in fact be deleterious (3). The current count of "uremic toxins" is in the three-digit range (4) . Which should clinicians target and how should we prioritize? Does one always aim to bring a parameter back to its normal range as defined in the nonuremic state? This is certainly not true for hematocrit and parathyroid hormone (PTH) (5-7), where a "new normal" for the uremic state is yet to be identified. Even for a simple marker such as urea, the effect on clinical outcome follows a "J curve," so "thelower-the-better" approach is not universally valid. An important factor to consider in this context is FGF23.
Troublemaker, bystander, or wrongly accused?
Since the cloning of FGF23 based on mutations in uncommon diseases (8, 9) , this peptide has earned a reputation as the new "bad guy in town" in the CKD world. The current view of FGF23 is that it is one of the most important phosphate-regulatory hormones that acts on multiple organs to maintain homeostasis (10) . It is quite unusual to witness an endocrine disorder in which the level of the deranged hormone reaches three orders of magnitude higher than the normal state. However, one encounters one epidemiologic study after another that links such high FGF23 levels to poor clinical out-myopathy in CKD (12) . If there is truth to this model, one may not want to obliterate FGF23 but rather direct FGF23 back to its more physiologic actions, perhaps by restoring Klotho levels.
Looking ahead
In sum, one should not view the study of Shalhoub and coworkers as a nihilistic "show stopper" in designing FGF23-related therapeutics in CKD. Instead, it should alert the field of the need to abandon the overly simplistic FGF23 toxicity model. Efforts should be directed toward defining the roles of FGF23 in physiology and CKD. What is actually driving up the FGF23 levels in CKD? What are the optimal levels in various stages of CKD for its different roles? What are the ways to enhance endogenous on-target signaling as adaptive reactions and decrease the off-target effects? Instead of finding the singular magic bullet, perhaps derangements of mineral metabolism need to be attacked at multiple loci. FGF23 is likely both friend and foe in CKD, and much knowledge and wisdom needs to be secured before we can move toward therapeutic applications.
